Core Points - SenesTech, Inc. announced the closing of the exercise of outstanding warrants to purchase 1,458,872 shares of common stock at an exercise price of $2.90 per share, generating approximately $4.4 million in gross proceeds [1][4] - The company issued new unregistered short-term warrants for the same number of shares at an exercise price of $4.15 per share, with a purchase price of $0.125 per warrant, potentially raising an additional $6.0 million if fully exercised [3][4] - The net proceeds from the transaction are intended for working capital and general corporate purposes [4] Company Overview - SenesTech is focused on humane management of animal pest populations through fertility control, having developed products like ContraPest®, the only U.S. EPA-registered contraceptive for rats, and Evolve™ products for rodents [8]

SURPRISE, Ariz., July 1, 2025 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES, "SenesTech" or the "Company"), a leader in fertility control for managing animal pest populations, announced today the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase an aggregate of 1,458,872 shares of the Company's common stock originally issued by the Company on March 11, 2025, at the existing exercise price of $2.90 per share. The closing of the warrant exercise transactio ...

Pallet and Container Orders Expected for Resupply and ExpansionSURPRISE, Ariz., June 26, 2025 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES, "SenesTech" or the "Company"), a leader in fertility control for managing animal pest populations, today announced compelling results from two major urban deployments — one in Hong Kong and one in San Francisco — showing how pairing Evolve™ Rat Birth Control with traditional poison bait stations delivers faster, more sustainable rodent control where it's needed most.Gl ...

"This project highlights how community-driven action and science-based solutions can work together to support sustainability," said Joel Fruendt, President and CEO of SenesTech. "Evolve aligns with these goals by providing a non-lethal, poison-free solution to rodent control." Evolve was deployed across 267 bait stations previously containing rodenticides and snap traps. According to field observations, rats consumed 98% of Evolve across all stations each month, indicating high acceptance and performance of ...

Strategic Partnership Expands National Reach and Accelerates Retail & Dealer Access Across Rural America SURPRISE, Ariz., June 11, 2025 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES, "SenesTech" or the "Company"), the leader in fertility control for managing animal pest populations, today announced a distribution agreement with Bradley Caldwell, Inc. (BCI), a premier wholesale distributor serving over 8,000 farm, ranch, hardware, and pet supply dealers across the United States. This new partnership signific ...

Summary of SenesTech (SNES) 2025 Conference Call Company Overview - **Company**: SenesTech, a biotech and life sciences company focused on rodent control through reproductive management rather than lethal methods [5][6] - **Ticker Symbol**: SNES, traded on NASDAQ [4] Core Product and Market Strategy - **Flagship Product**: Evolve, launched in 2024, is a soft bait designed for rodent fertility control, which has quickly become the top-selling product [12][14] - **Sales Growth**: Evolve sales grew by 40% year-over-year in Q1 2025 [15][37] - **Market Opportunity**: The U.S. rodenticide market is estimated at $1 billion annually, with a global market of $4.5 billion [34] Unique Selling Proposition - **Sustainable Approach**: Focus on controlling the birth rate of rodents rather than relying on poisons, which have social, political, and ecological drawbacks [6][8][30] - **Product Safety**: Evolve is designated as a minimum risk product by the EPA, using cottonseed oil as the active ingredient, making it safer for pets and wildlife [14][16] Distribution Channels - **Six Channel Strategy**: Includes e-commerce, agriculture distributors, pest management distributors, retail (e.g., Ace Hardware), international distributors, and direct sales to large customers [18][19] - **E-commerce Growth**: E-commerce sales increased by over 7%, with a run rate approaching $60,000 to $70,000 per month [20][21] Municipal and International Opportunities - **Municipal Deployments**: Significant projects in Chicago and New York City, with repeat orders indicating product effectiveness [23][24][25] - **International Expansion**: Exclusive distribution agreements signed in 12 countries, with expected approvals in Australia and New Zealand [27][28] Financial Performance - **Revenue Growth**: Record revenue of $1.9 million in 2024, up 56% from the previous year [39] - **Gross Margin Improvement**: Gross margins for Evolve reached 64%, compared to 32% in Q1 of the previous year [40] - **Cost Optimization**: Initiatives to reduce operating costs include pausing new product development and optimizing sales efforts [44] Future Outlook - **Path to Profitability**: Aiming for cash flow breakeven at approximately $1.5 million per quarter, with current revenues around $500,000 per quarter [45][46] - **Market Trends**: Increasing awareness of the need for humane rodent control solutions due to public health concerns and regulatory changes [52][53] Key Takeaways - **Transformative Opportunity**: SenesTech believes it has a paradigm-changing product that addresses long-standing rodent control issues in a sustainable manner [55][56] - **Execution Strategy**: Focus on expanding market presence, improving product offerings, and enhancing operational efficiencies to drive future growth [54][56]

Company Participation - SenesTech, Inc. will participate in a webcast fireside chat and host one-on-one meetings with investors at the Lytham Partners Spring 2025 Investor Conference on May 29, 2025 [1] - The webcast presentation is scheduled for 3:30 p.m. ET and will be accessible via the conference home page or directly through a provided link [2] - Management will engage in virtual one-on-one meetings throughout the event, with arrangements available through Lytham Partners [3] Company Overview - SenesTech is focused on improving global health by managing animal pest populations through fertility control solutions [4] - The company developed ContraPest, the only U.S. EPA-registered contraceptive for male and female rats, along with Evolve and Evolve Mouse, which are EPA-designated minimum risk contraceptives for rodents [4] - SenesTech aims to integrate its products into pest management programs to enhance effectiveness and promote humane, safe, and sustainable pest control [4]

Senestech (SNES) Q1 2025 Earnings Call May 08, 2025 05:00 PM ET Company Participants Robert Blum - Managing PartnerJoel Fruendt - CEO & DirectorTom Chesterman - CFO Operator After today's presentation, there will be an opportunity to ask questions. Please note this event is being recorded. I would now like to turn the conference over to Robert Blum with Lytham Partners. Please go ahead. Robert Blum All right. Thanks so much, and thank you all for joining us today to discuss SenesTech's first quarter twenty ...

Senestech (SNES) Q1 2025 Earnings Call May 08, 2025 05:00 PM ET Speaker0 After today's presentation, there will be an opportunity to ask questions. Please note this event is being recorded. I would now like to turn the conference over to Robert Blum with Lytham Partners. Please go ahead. Speaker1 All right. Thanks so much, and thank you all for joining us today to discuss SenesTech's first quarter twenty twenty five financial results for the period ended 03/31/2025. With us on the call today are Joel Fruint ...

SURPRISE, Ariz., May 8, 2025 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES), the leader in fertility control for managing animal pest populations and the only manufacturer of EPA-registered rodent birth control products today announced its financial results for the first quarter ended March 31, 2024.Q1 2025 Highlights Revenues increased 17% to $485,000 from $415,000 in Q1 2024. Evolve product sales grew 40% year-over-year, now representing 79% of total revenue. Gross profit margin expanded to 64.5%, a recor ...